A detailed history of Polar Capital Holdings PLC transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Polar Capital Holdings PLC holds 825,795 shares of PCVX stock, worth $37.4 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
825,795
Previous 1,082,473 23.71%
Holding current value
$37.4 Million
Previous $40.9 Million 34.32%
% of portfolio
0.15%
Previous 0.27%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$28.04 - $37.2 $7.2 Million - $9.55 Million
-256,678 Reduced 23.71%
825,795 $26.8 Million
Q1 2025

May 15, 2025

BUY
$37.76 - $92.13 $4.11 Million - $10 Million
108,828 Added 11.18%
1,082,473 $40.9 Million
Q4 2024

Feb 14, 2025

SELL
$80.97 - $117.93 $1.79 Million - $2.61 Million
-22,134 Reduced 2.22%
973,645 $79.7 Million
Q3 2024

Nov 14, 2024

BUY
$70.52 - $117.12 $70.2 Million - $117 Million
995,779 New
995,779 $114 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.69B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Polar Capital Holdings PLC Portfolio

Follow Polar Capital Holdings PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Polar Capital Holdings PLC, based on Form 13F filings with the SEC.

News

Stay updated on Polar Capital Holdings PLC with notifications on news.